– USA, WA – Visus Therapeutics Inc., a clinical-stage pharmaceutical company developing innovative ophthalmic therapies to improve vision for people around the world, today announced the appointments of Tracy Valorie and Dwight Moxie to its Board of Directors.
Tracy Valorie is the former SVP and GM, US Ophthalmology Rx and Surgical at Bausch + Lomb, and Dwight Moxie is SVP, General Counsel, and Corporate Secretary at Revance Therapeutics, Inc.
“I am very pleased to welcome Tracy Valorie and Dwight Moxie to Visus Therapeutics’ Board of Directors,” said co-founder and CEO, Ben Bergo. “Both of these renowned leaders possess expertise across many industries and will be invaluable as we continue to grow our portfolio of novel compounds and advance our lead program, BRIMOCHOL, in development for the treatment of presbyopia. I look forward to their strategic insights and contributions to achieve our mission of dramatically improving patients’ lives by developing differentiated best-in-class ophthalmic therapies.”
About Tracy Valorie
Tracy Valorie brings deep expertise with 25 years of experience in the pharmaceutical and biotech industries spanning strategic business counsel, commercial development, brand and customer marketing, and clinical development and research. Ms. Valorie previously served as SVP and General Manager of US Ophthalmology Rx and Surgical at Bausch + Lomb. Before that, she held numerous leadership positions at Pfizer where she led commercial development for the company’s global Ophthalmology Franchise, including Xalatan and Xalacom for glaucoma. In her previous roles, she was responsible for collaborating with enterprising companies and evaluating novel technologies for potential partnerships. She is currently on the advisory board of Ophthalmic World Leaders.
“I am honored to join Visus Therapeutics’ Board of Directors and am looking forward to working with this talented and capable team,” said Tracy Valorie. “BRIMOCHOL has the potential to be a real-world solution for people living with presbyopia, and I am excited to be an integral part of the organization developing a best-in-class pipeline of ophthalmic products under Ben’s leadership.”
Ms. Valorie holds an MBA from Rensselaer Polytechnic Institute and a Bachelor of Science in Molecular Biology from the University of Connecticut.
About Dwight Moxie
Dwight Moxie is the General Counsel, SVP, and Corporate Secretary at Revance Therapeutics. Mr. Moxie leads legal, governance, and compliance for the company, and brings more than two decades of experience in the biopharmaceutical and healthcare sectors, advising and supporting companies developing and commercializing novel drugs. Previously, he served as the VP, Deputy General Counsel at Ultragenyx, and held various legal counsel positions at Allergan and GlaxoSmithKline. Throughout his career, Mr. Moxie has led teams in commercial operations, litigation, research and development, regulatory, product marketing, and mergers and acquisitions.
“I’m proud to be involved with a company that is dedicated to creating a new generation of best-in-class ophthalmic therapies,” said Dwight Moxie. “I look forward to working alongside Visus Therapeutics’ outstanding management team to advance the company’s lead investigational candidate for the treatment of presbyopia, BRIMOCHOL, and its robust pipeline of novel ophthalmic therapies.”
He holds a J.D. degree from Howard University School of Law and a Bachelor of Arts in Social Science from Florida State University.
About Visus Therapeutics
Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma, and age-related macular degeneration.
For more information: https://www.visustx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
